Analysis of the standardization and influential factors in the prevention and treatment of glucocorticoid-induced osteoporosis with drugs

JIANG Wenshuo; LIU Chen; ZENG Yan

doi:10.6039/j.issn.1001-0408.2025.08.18

您当前的位置：

首页 >

文章列表页 >

Analysis of the standardization and influential factors in the prevention and treatment of glucocorticoid-induced osteoporosis with drugs

更新时间：2025-09-23

- Analysis of the standardization and influential factors in the prevention and treatment of glucocorticoid-induced osteoporosis with drugs
- ZHONGGUO YAOFANG Vol. 36, Issue 8, Pages: 991-995(2025)
- 作者机构：
  
  1.首都医科大学宣武医院药学部，北京　100037
  2.首都医科大学药学院，北京　100069
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.08.18
  CLC： R977.1+1
- Received：27 September 2024，
  
  Revised：2025-03-23，
  
  Accepted：24 March 2025，
  
  Published：30 April 2025
- 稿件说明：
移动端阅览
蒋文硕,刘琛,曾艳.药物防治糖皮质激素性骨质疏松的规范性及影响因素分析 [J].中国药房,2025,36(08):991-995.

JIANG Wenshuo,LIU Chen,ZENG Yan.Analysis of the standardization and influential factors in the prevention and treatment of glucocorticoid-induced osteoporosis with drugs[J].ZHONGGUO YAOFANG,2025,36(08):991-995.
蒋文硕,刘琛,曾艳.药物防治糖皮质激素性骨质疏松的规范性及影响因素分析 [J].中国药房,2025,36(08):991-995. DOI： 10.6039/j.issn.1001-0408.2025.08.18.

JIANG Wenshuo,LIU Chen,ZENG Yan.Analysis of the standardization and influential factors in the prevention and treatment of glucocorticoid-induced osteoporosis with drugs[J].ZHONGGUO YAOFANG,2025,36(08):991-995. DOI： 10.6039/j.issn.1001-0408.2025.08.18.

摘要

目的

分析糖皮质激素性骨质疏松（GIOP）防治药物使用的规范性和影响因素。

方法

回顾性收集2022年1月1日至2023年12月31日于我院诊断为风湿免疫性疾病的需长期使用糖皮质激素的住院患者资料。分析患者的GIOP骨折风险分层及防治药物使用情况；采用单因素分析和Logistic逐步回归分析筛选影响患者防治药物使用规范性的因素。

结果

354例患者中，148例患者（41.81%）的骨折风险为低度，103例患者（29.10%）为中度，103例患者（29.10%）为高度；GIOP防治药物使用排名前3位的分别为钙剂（78.81%）、维生素D制剂（74.01%）、抗骨质疏松药物（21.19%）。133例（37.57%）患者规范使用了GIOP防治药物，低度骨折风险患者的防治规范率显著高于高度和中度骨折风险患者，且高度骨折风险患者显著高于中度骨折风险患者（

＜0.05）。单因素分析结果显示，低度骨折风险是GIOP防治药物使用规范性的保护因素，中度骨折风险、吸烟或饮酒、出现药物不良反应以及大专以下文化程度是其危险因素（

＜0.05）。Logistic逐步回归分析结果显示，有低、中度骨折风险，有吸烟或饮酒史，服用抗骨质疏松药物后出现不良反应患者的防治规范率较低，而既往1个月就诊三甲医院、使用糖皮质激素时间更长患者的防治规范率较高（

＜0.05）。

结论

我院GIOP防治药物的使用规范率较低；中、高度骨折风险，吸烟或饮酒史，服用抗骨质疏松药物后出现不良反应患者的防治规范率较低，而既往1个月就诊于三甲医院、使用糖皮质激素时间更长患者的防治规范率较高。

Abstract

OBJECTIVE

To analyze the standardization and influential factors medication use for the prevention and treatment of glucocorticoid-induced osteoporosis （GIOP）.

METHODS

The data of inpatients diagnosed as rheumatic immune diseases in our hospital from January 1， 2022， to December 31， 2023， who required long-term use of glucocorticoids， were collected to analyze the risk stratification for GIOP-related fractures and the utilization of prevention and treatment drug in patients. Univariate analysis and Logistic stepwise regression analysis were employed to screen the factors influencing the standardization of prevention and treatment drug use in patients.

RESULTS

Among 354 patients， 148 patients （41.81%） had a low risk of osteoporotic fractures， 103 patients （29.10%） had a moderate risk， and 103 patients （29.10%） had a high risk. The top three drugs used in the prevention and treatment of GIOP were calcium supplements （78.81%）， vitamin D preparations （74.01%）， and anti-osteoporosis drugs （21.19%）. A total of 133 patients （37.57%） used the drugs for GIOP prevention and treatment in a standardized manner. The standardization rate of prevention and treatment in patients with low fracture risk was significantly higher than those with high and moderate fracture risk， and the standardization rate in patients with high fracture risk was significantly higher than those with moderate fracture risk （

＜0.05）. Besides， the univariate analysis showed that low fracture risk served as a prevention factor for the standardized use of prevention and treatment drugs for GIOP， while moderate fracture risk， smoking or drinking， the occurrence of adverse drug reactions， and having an educational level below junior college were risk factors for the normative use of GIOP prevention and treatment drug （

＜0.05）. Logistic stepwise regression analysis showed that patients with low and moderate fracture risk， a history of smoking or drinking， and adverse drug reactions to anti-osteoporosis drugs had a lower standardization rate of prevention and treatment； patients who visited tertiary hospital for the past month and had a longer duration of glucocorticoid use had a higher standardization rate of prevention and treatment （

＜0.05）.

CONCLUSIONS

The standardized rate of prevention and treatment drugs used for GIOP in our hospital is relatively low. Patients with moderate to high fracture risk， a history of smoking or drinking， and those who experience adverse drug reactions after taking anti-osteoporosis drugs have lower rates of standardized prevention and treatment. Conversely， patients who sought treatment at tertiary hospital for the past month and had a longer duration of glucocorticoid had higher rates of standardized prevention and treatment.

关键词

Keywords

references

ANASTASILAKI E ， PACCOU J ， GKASTARIS K ， et al . Glucocorticoid-induced osteoporosis：an overview with focus on its prevention and management [J ] . Hormones（Athens）， 2023 ， 22 （ 4 ）： 611 - 622 .

POFI R ， CARATTI G ， RAY D W ， et al . Treating the side effects of exogenous glucocorticoids；can we separate the good from the bad? [J ] . Endocr Rev ， 2023 ， 44 （ 6 ）： 975 - 1011 .

HUMPHREY M B ， RUSSELL L ， DANILA M I ， et al . 2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis [J ] . Arthritis Rheumatol ， 2023 ， 75 （ 12 ）： 2088 - 2102 .

TANAKA Y ， SOEN S ， HIRATA S ， et al . The 2023 Guidelines for the management and treatment of glucocorticoid-induced osteoporosis [J ] . J Bone Miner Metab ， 2024 ， 42 （ 2 ）： 143 - 154 .

CHO S K ， SUNG Y K . Update on glucocorticoid induced osteoporosis [J ] . Endocrinol Metab（Seoul）， 2021 ， 36 （ 3 ）： 536 - 543 .

CARTER M . Prevention of glucocorticoid-induced osteoporosis：clinical audit to evaluate the implementation of national osteoporosis guideline group 2017 guidelines in a primary care setting [J ] . J Clin Densitom ， 2019 ， 22 （ 1 ）： 25 - 30 .

张学武，姚海红，梅轶芳，等 . 全国多中心使用糖皮质激素风湿病患者骨质疏松调查 [J ] . 中华临床免疫和变态反应杂志， 2017 ， 11 （ 3 ）： 277 - 284 .

纪宗斐，张卓君，鲍春德，等 . 糖皮质激素相关骨质疏松的流行病学调查 [J ] . 中华风湿病学杂志， 2014 ， 18 （ 8 ）： 520 - 524 .

何菁，李芬，黄文辉，等 . 糖皮质激素性骨质疏松症的诊疗规范 [J ] . 中华内科杂志， 2023 ， 62 （ 6 ）： 631 - 638 .

CHOTIYARNWONG P ， MCCLOSKEY E V . Pathoge-nesis of glucocorticoid-induced osteoporosis and options for treatment [J ] . Nat Rev Endocrinol ， 2020 ， 16 （ 8 ）： 437 - 447 .

WANG L T ， CHEN L R ， CHEN K H . Hormone-related and drug-induced osteoporosis：a cellular and molecular overview [J ] . Int J Mol Sci ， 2023 ， 24 （ 6 ）： 5814 .

BILLUPS S J ， THAI V K ， DENKINS J ， et al . Bad to the bones：prescribing of drugs for the prevention and treatment of osteoporosis in patients on chronic glucocorticoids [J ] . Arch Osteoporos ， 2023 ， 18 （ 1 ）： 38 .

IKI M ， FUJIMORI K ， NAKATOH S ， et al . Real-world effectiveness of anti-osteoporosis medications for the prevention of incident hip and clinical vertebral fractures in patients on long-term glucocorticoid therapy：a nationwide health insurance claims database study in Japan [J ] . Bone ， 2023 ， 166 ： 116605 .

BJORNSDOTTIR H H ， EINARSSON Ó B ， GRÖNDAL G ， et al . Nationwide prevalence of glucocorticoid prescriptions over 17 years and osteoporosis prevention among long-term users [J ] . SAGE Open Med ， 2024 ， 12 ： 20503121241235056 .

中国医师协会风湿免疫科医师分会，中华医学会风湿病学分会，中华医学会骨质疏松和骨矿盐疾病分会，等 . 2020版中国糖皮质激素性骨质疏松症防治专家共识 [J ] . 中华内科杂志， 2021 ， 60 （ 1 ）： 13 - 21 .

SAPKOTA S ， BAIG S ， HESS T ， et al . Vitamin D and bisphosphonate therapy in systemic lupus erythematosus patients who receive glucocorticoids：are we offering the best care? [J ] . Lupus ， 2020 ， 29 （ 3 ）： 263 - 272 .

ABDULLAH H ， KOLLER G ， ZUNA I ， et al . Evaluation of care delivery by a novel multidisciplinary bone health clinic for patients at risk of glucocorticoid-induced osteoporosis [J ] . Arch Osteoporos ， 2021 ， 16 （ 1 ）： 108 .

KO D ， FORREST N ， MAI Q ， et al . Electronic health record data use in the assessment of quality indicators for glucocorticoid osteoporosis screening in systemic lupus erythematosus [J ] . Lupus ， 2022 ， 31 （ 12 ）： 1516 - 1522 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical efficacy and influencing factors of ceftazidime and avibactam monotherapy versus combination therapy in the treatment of CRGNB infection

Study on the influential factors for clinical efficacy of polymyxin B combined with other antibiotics in the treatment of carbapenem-resistant Acinetobacter baumannii pulmonary infection

Investigation on the current status of pharmaceutical care in medical institutions in China

Characteristics and influencing factors of immune-related adverse events in patients with extensive-stage small cell lung cancer treated with immune checkpoint inhibitors

Analysis of influencing factors on the inclusion of Chinese patent medicines in the national reimbursement drug list

Related Author

LIU Changwei

WANG Xiaohua

ZHANG Hui

WANG Ranran

XIAO Rongcheng

FANG Ling

DU Mei

TAN Ruijuan

Related Institution

Dept. of Infectious Diseases， the First Affiliated Hospital of Anhui Medical University

Grade Ⅲ Pharmaceutical Chemistry Laboratory of TCM， National Administration of Traditional Chinese Medicine

Dept. of Pharmacy， the First Affiliated Hospital of Anhui Medical University

Dept. of Rehabilitation Medicine， Hengshui Municipal People’s Hospital

Dept. of Pharmacy， Hengshui Municipal People’s Hospital

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰